ABL1 (ABL proto-oncogene 1)

P=N/A, N=10, Active, not recruiting, University College, London | Recruiting --> Active, not recruiting

Blinatumomab achieved high short-term MRD response rates in high-risk B-ALL. Inferior outcomes appeared to be associated with the presence of BCR::ABL1 T315I mutations and E2A::PBX1 rearrangements.

Cellular Ki values of dasatinib and imatinib for 25 kinases by FPCBA were broadly concordant with kinobead LC/MS measurements in cancer cell lysates but diverged substantially from recombinant KINOMEscan values, with divergences attributable to competition with ATP, autoinhibition, and membrane-dependent conformational states in living cells. FPCBA enables profiling of native protein-small molecule interactions in a physiologically relevant cellular context.

CD26 + LSCs can be a useful marker in follow up of patients with CML. Despite promising findings, the limited sample size highlight the need for larger, prospective studies to validate these results and assess the predictive value of CD26 + LSCs for TKI discontinuation strategies.

Additionally, on mathematical models of the BCR::ABL1 transcripts after initiation of TFR, distinct patterns in the kinetics in sustained and relapsed patients was identified. Our findings support a modified, risk-adapted TFR monitoring strategy for low- and middle-income countries (LMICs) to enhance surveillance while optimizing resource utilization.

Imatinib & Dasatinib Are Two Most Commonly Used Tyrosine Kinase Inhibitor (TKI) for Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). One (1) patient developed grade 3 pleural effusion & succumbed to complication. 20% patients failed to achieve optimum molecular response at 6 month with most common adverse effect being neutropenia.

The patient was treated with cytoreductive therapy, followed by imatinib, with a favorable clinical and hematologic response. This case highlights the potential for massive splenomegaly to mask CML and emphasizes the importance of early molecular testing. Splenectomy may unmask underlying hematologic malignancy through significant postoperative hematologic changes.

P2, N=131, Completed, Versailles Hospital | Active, not recruiting --> Completed

P1/2, N=14, Recruiting, Novartis Pharma AG | Not yet recruiting --> Recruiting

Moreover, N-acetylcysteine inhibited CCCP-induced reactive oxygen species production, prevented mitochondrial translocation of p210 BCR-ABL, and fully restored ERK-activation. These findings suggest that intercellular relocation of p210 BCR-ABL dynamically rewires downstream signaling networks, potentially optimizing the signaling balance required for CML cell survival and proliferation.

Vodobatinib demonstrates a favorable preclinical absorption, distribution, metabolism, and excretion profile, with high metabolic stability, minimal efflux liability, and selective tissue distribution. These findings support its continued clinical development in chronic myeloid leukemia and potentially other Bcr-Abl 1 driven malignancies.

P1, N=30, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting